What are the goal targets and medications for a patient with Hypertrophic Obstructive Cardiomyopathy (HOCM) status post (s/p) myomectomy?

Post-Myomectomy Management for HOCM

Goal Targets After Myomectomy

The primary hemodynamic goal after successful septal myectomy is maintaining an LVOT gradient <30 mmHg at rest, with most patients achieving complete elimination of obstruction (gradient 0-10 mmHg). 1, 2

Specific Hemodynamic Targets:

• Resting heart rate: 60-65 bpm to ensure adequate diastolic filling time 3, 4
• LVOT gradient: <30 mmHg (ideally <10 mmHg) at rest and with provocation 1, 2
• Blood pressure: Maintain adequate afterload to prevent residual dynamic obstruction 3
• Avoid hypovolemia: Maintain adequate preload as this is the most common precipitant of hemodynamic collapse 3

Functional Targets:

• NYHA functional class improvement by ≥1 class (90-95% of patients achieve this) 1, 2
• Normal exercise capacity on stress testing 1
• Resolution or significant reduction of mitral regurgitation 1

---

Medication Management Post-Myomectomy

Continue Beta-Blockers Perioperatively and Long-Term

Beta-blockers remain the cornerstone of medical therapy even after successful myomectomy and should be continued without interruption. 1, 3, 4

• Rationale: Beta-blockers provide negative inotropic effects, prevent tachycardia, prolong diastolic filling, and reduce myocardial oxygen demand 1, 4
• Target dose: Titrate to achieve resting heart rate <60-65 bpm with physiologic beta-blockade 4, 5
• Critical warning: Abrupt discontinuation can precipitate rebound tachycardia and worsening symptoms 3

Non-Dihydropyridine Calcium Channel Blockers (Alternative or Adjunct)

Verapamil or diltiazem may be continued if the patient was on them pre-operatively, but should NOT be combined with beta-blockers due to risk of severe bradycardia and heart block. 1, 3, 5

• Use cautiously in patients with residual obstruction, elevated pulmonary artery wedge pressure, or low systemic blood pressure, as they may trigger increased outflow obstruction and precipitate pulmonary edema 1, 3
• Dosing: Verapamil up to 480 mg/day if tolerated 4

Disopyramide (If Residual Obstruction)

For patients with residual symptomatic obstruction post-myomectomy despite beta-blockers or calcium channel blockers, disopyramide may be added. 1, 5

• This is reserved for refractory cases with persistent LVOT gradient ≥50 mmHg 1

Diuretics (Use Judiciously)

Low-dose diuretics may be used for pulmonary congestion, but must be used cautiously to avoid excessive preload reduction. 1, 5

• High-dose diuretics should be avoided as they can precipitate hemodynamic collapse by reducing preload excessively 1, 3, 4

---

Medications to AVOID Post-Myomectomy

Absolute Contraindications:

• Dihydropyridine calcium channel blockers (nifedipine, amlodipine): Vasodilation worsens any residual LVOT obstruction 1, 3, 4, 5
• Positive inotropes (dopamine, dobutamine, digoxin): Increase contractility and worsen obstruction 3, 4
• Pure vasodilators (ACE inhibitors, ARBs, nitrates, hydralazine): Reduce afterload and can precipitate obstruction 3, 4, 5

Critical Pitfall:

Never combine beta-blockers with non-dihydropyridine calcium channel blockers (verapamil/diltiazem) as this causes severe bradycardia and high-grade AV block. 3, 5

---

Hemodynamic Crisis Management (If Residual Obstruction)

If hemodynamic collapse occurs due to residual LVOT obstruction with mitral regurgitation, immediately administer phenylephrine to increase afterload. 3

• Phenylephrine is the preferred agent for acute hypotension 3
• Alternative: Vasopressin (alpha-agonist) 3
• Avoid: Beta-agonists, vasodilators, or inotropes as they worsen obstruction 3

---

Surveillance and Follow-Up Targets

Echocardiographic Monitoring:

• Repeat TTE at 3-6 months post-myomectomy to assess residual gradient and LV remodeling 1, 4
• Annual TTE thereafter in stable patients 4
• Assess for: Residual LVOT gradient, mitral regurgitation, left atrial size reduction, and LV reverse remodeling 1

Arrhythmia Surveillance:

• 24-48 hour Holter monitoring every 1-2 years for ventricular arrhythmia detection and sudden cardiac death risk stratification 4
• Annual 12-lead ECG 4

Atrial Fibrillation Management:

All patients with HCM who develop atrial fibrillation require oral anticoagulation (direct oral anticoagulants or warfarin) regardless of CHA₂DS₂-VASc score due to inherently high stroke risk. 1, 4

---

Lifestyle and Comorbidity Management

Exercise:

• Mild to moderate-intensity recreational exercise is beneficial for improving cardiorespiratory fitness and quality of life 1, 4
• Avoid dehydration and maintain adequate fluid intake 1, 4

Comorbidities:

• Hypertension: Treat with beta-blockers or non-dihydropyridine calcium channel blockers as first-line agents 1
• Obesity: Weight loss interventions reduce risk of heart failure, atrial fibrillation, and adverse outcomes 1
• Sleep-disordered breathing: Screen and refer to sleep medicine specialist if present 1

---

When to Consider Re-Intervention

Recurrent outflow tract obstruction after myectomy is rare (<5%), but if symptoms recur with LVOT gradient ≥50 mmHg despite optimal medical therapy, consider repeat septal reduction therapy at an experienced HCM center. 1

• Surgical myectomy remains the gold standard with operative mortality <1% at experienced centers and 90-95% clinical success rate 1, 2
• Alcohol septal ablation may be considered in older patients or those with high surgical risk 1